Caris Life Sciences and Xencor, Inc. expanded their collaboration to research, develop, and commercialize novel XmAb bispecific and multi-specific antibodies directed against novel targets, identified and proposed by Caris, for the treatment of patients with cancer.
Exscientia plc announced it will be expanding its work with Amazon Web Services to use the cloud provider’s artificial intelligence and machine learning services to power its platform for end-to-end drug discovery and automation.
